{
    "nctId": "NCT06338644",
    "briefTitle": "Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.",
    "officialTitle": "Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "1-year Progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Adult patients (\u226518 years). 2. Confirmed diagnosis with MBC. 3. HR-positive/HER2-negative MBC as ascertained by immunohistochemistry (IHC) or fluorescence in situ hybridization in primary or metastatic tissue samples.\n\n  4. Patients with primary or secondary resistance to endocrine therapy. 5. Patients with Eastern Cooperative Oncology Group (ECOG) 0 or 1. 6. Scheduled to receive Palbociclib in first- or second-line metastatic setting.\n\nExclusion Criteria:\n\n1. Prior exposure to fulvestrant or everolimus.\n2. Patients with uncontrolled brain metastases or symptomatic visceral spread who are at risk of life-threatening complications.\n3. Patients refusing to sign the written informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}